Catalyst Pharmaceuticals stock hits all-time high at $26.63 By Investing.com

robot
Abstract generation in progress

Catalyst Pharmaceuticals stock reached an all-time high of $26.63, trading within 1% of its 52-week high, driven by a 12.2% total return over the past year and a 25% gain in the last six months. The company’s financial strength is highlighted by holding more cash than debt, and its stock appears undervalued based on InvestingPro analysis with a P/E ratio of 15.65 and a PEG ratio of 0.52. Recent strong Q4 2025 financial results, with EPS and revenue significantly exceeding forecasts, and ongoing research into Duchenne muscular dystrophy further contribute to investor confidence.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin